Alpha Teknova, Inc. Common Stock
TKNOAlpha Teknova, Inc. (TKNO) is a biotechnology company that develops and supplies essential reagents and materials for the healthcare and life sciences industries. Focused on providing high-quality products for diagnostics, pharmaceutical research, and other laboratory applications, Teknova supports scientific discovery and clinical testing through innovation and reliable supply chains.
Company News
Teknova and Pluristyx are collaborating to produce and commercialize Pluristyx's PluriFreeze cryopreservation system, which is designed to simplify the scale-up process for companies working to bring allogeneic cell therapies to market.
Telegraph Hill Partners, a major shareholder in Alpha Teknova, Inc., has increased its stake in the company through a private placement, purchasing shares worth approximately $15 million at $1.24 per share. This transaction reflects a positive outlook from Telegraph Hill Partners on Alpha Teknova's future prospects.
Alpha Teknova (TKNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Alpha Teknova (TKNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
First quarter 2024 total revenue was $9.3 million, up 2% from prior yearLaunch of Build-Tek™ Custom ConfiguratorCompany reaffirms 2024 revenue guidance of $35-38 million
